-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ruvembri in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ruvembri in Obesity report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ruvembri in Obesity Drug Details: BIO-101 (SARCONEOS) is under development for the...
-
Product Insights
NewJuvenile Macular Degeneration (Stargardt Disease) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Juvenile Macular Degeneration Clinical Trial Report Overview A total of 59 Juvenile Macular Degeneration clinical trials were conducted as of April 2024. The Juvenile Macular Degeneration clinical trial report provides a comprehensive understanding of the Juvenile Macular Degeneration clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions...
-
Product Insights
NewMuscular Dystrophy – Drugs In Development, 2024
Empower your strategies with our Muscular Dystrophy – Drugs In Development, 2024 report and make more profitable business decisions. Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness, and progressive difficulty walking. The Muscular Dystrophy drugs in development market research report provide comprehensive information on...
-
Product Insights
NewJuvenile Macular Degeneration (Stargardt Disease) – Drugs In Development, 2024
Empower your strategies with our Juvenile Macular Degeneration (Stargardt Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Juvenile macular degeneration is a series of inherited eye disorders that affects children and young adults. The most common form of juvenile macular degeneration is Stargardt disease, an inherited autosomal recessive syndrome. Signs and symptoms include blurry or fuzzy vision; dark, empty spots in the center of vision; and difficulty reading or performing detail work. Risk factors include arteriosclerosis,...
-
Product Insights
NewRetinopathy – Drugs In Development, 2024
Empower your strategies with our Retinopathy – Drugs In Development, 2024 report and make more profitable business decisions. Retinopathy is any damage to the retina of the eyes, which may cause vision impairment. Retinopathy often refers to retinal vascular disease, or damage to the retina caused by abnormal blood flow. Retinopathy, or retinal vascular disease, can be broadly categorized into proliferative and non-proliferative types. Frequently, retinopathy is an ocular manifestation of a systemic disease such as diabetes or hypertension. The Retinopathy...
-
Product Insights
NewSarcopenia – Drugs In Development, 2024
Empower your strategies with our Sarcopenia – Drugs In Development, 2024 report and make more profitable business decisions. Sarcopenia is an aging-associated condition which is characterized by loss of muscle mass, strength, and function. Symptoms include weakness, loss of endurance, and poor balance. Causes of sarcopenia include a loss of nerve cells, low hormone levels, and a decline in the body’s ability to convert protein to energy. Treatment includes hormone replacement therapy (HRT), exercise, and dietary supplements. The Sarcopenia drugs in...
-
Product Insights
NewRespiratory Failure – Drugs In Development, 2024
Empower your strategies with our Respiratory Failure – Drugs In Development, 2024 report and make more profitable business decisions. The respiratory system allows gas exchange between the environment and the body, facilitating the process of aerobic metabolism. Specifically, the respiratory system provides oxygen and removes carbon dioxide from the body. The inability of the respiratory system to perform either or both of these tasks results in respiratory failure. Respiratory failure can be classified based on chronicity: acute, chronic, and acute on...
-
Product Insights
NewInfluenzavirus A Infections – Drugs In Development, 2024
Empower your strategies with our Influenzavirus A Infections – Drugs In Development, 2024 report and make more profitable business decisions. Influenza A virus infections are caused by a type of influenza virus with a high capacity for genetic variation. It is more serious than the common cold and can cause major outbreaks and severe disease. It spreads through droplets from the nose or throat of an infected person, usually through coughing and sneezing. The proteins on the surface of the influenza...